Hepatocellular carcinoma.
Hepatocellular carcinoma.
复制标题
DOI：
10.1016/j.cld.2006.05.012
复制
发表时间：
2006-05-01
影响因子：
5.1
通讯作者：
Pelletier, Shawn
中科院分区：
文献类型：
--
作者：
Marrero, Jorge A;Pelletier, Shawn
预计在未来1至20年内，患有肝细胞癌（HCC）的患者数量将增加一倍以上。肝硬化患者，无论原因如何，发展为HCC的风险最高。本文讨论了甲胎蛋白和超声监测这些患者的肝细胞癌，评价使用成像，分类的肝细胞癌使用巴塞罗那分期分类，和治疗。切除、移植和经皮消融被认为是治疗性干预，并应用于约30%的HCC患者。目前，对于晚期HCC还没有标准的治疗方法。
The number of patients who have hepatocellular carcinoma (HCC) is expected to more than double over the next 1 to 2 decades. Patients who have cirrhosis, regardless of cause, are at the highest risk for developing HCC. This article discusses surveillance of these patients for HCC by alpha-fetoprotein and ultrasound, evaluation using imaging, classification of HCC using the Barcelona staging classification, and treatment. Resection, transplantation, and percutaneous ablation are considered curative interventions and are applied to about 30% of all patients who have HCC. Currently, there is no standard therapy for advanced HCC.